Vertex Reports long-term follow-up Data for Trastuzumab in Focal segmental glomerulosclerosis

Vertex today announced long-term follow-up results for trastuzumab in patients with focal segmental glomerulosclerosis. The study demonstrated that trastuzumab reduces adverse events compared to standard of care or placebo. These results provide important insights into the treatment of focal segmental glomerulosclerosis and support the continued development of trastuzumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.